Video
Dr. Sharma Discusses Updates from CheckMate-275 in Bladder Cancer
Author(s):
Padmanee Sharma, MD, PhD, scientific director, Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, discusses updated findings from the CheckMate-275 trial in bladder cancer during an interview at the 2018 AACR Annual Meeting.
Padmanee Sharma, MD, PhD, scientific director, Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, discusses updated findings from the CheckMate-275 trial in bladder cancer during an interview at the 2018 AACR Annual Meeting.
Results from the CheckMate-275 trial previously confirmed the efficacy and safety of nivolumab (Opdivo) monotherapy in this population. Updated data showed that, at a median follow-up of 24.5 months, the overall response rate was 20.4% for all treated patients. In addition to the previously reported 17 complete responses (CRs), this update showed 9 more CRs.
Sharma says that immunotherapy should be considered as one of the primary pillars in treating patients with metastatic bladder cancer. She adds that there is a lot of information available on how to administer and manage patients on immunotherapies for the community oncologist.
